Genmab — M&A Activity 2012

Jul 12, 2012

News Details

Ad-hoc | 12 July 2012 21:09

Genmab Enters Broad Collaboration with Janssen Biotech, Inc. for DuoBody Platform

Genmab A/S

12.07.2012 21:09

Dissemination of a Adhoc News, transmitted by DGAP - a company of
EquityStory AG.
The issuer is solely responsible for the content of this announcement.

---

Company Announcement

-- Genmab enters DuoBody(tm) technology collaboration
-- $3.5 million upfront payment to Genmab

Copenhagen, Denmark; July 12, 2012 - Genmab A/S (OMX: GEN) announced today it
has entered into a collaboration with Janssen Biotech, Inc. and its affiliates
('Janssen') to create and develop bispecific antibodies using its DuoBody
technology platform. Genmab will create panels of bispecific antibodies to
multiple disease target combinations identified by Janssen, who will in turn
fully fund research at Genmab.

Under the terms of the agreement, Genmab and Janssen will collaborate on the
research of up to 10 DuoBody programs and Genmab will receive an upfront
payment of $3.5 million (DKK 21 million) from Janssen and all research by
Genmab will be fully funded by Janssen. In addition, Genmab will potentially be
entitled to milestone and license payments of up to approximately $175 million
(DKK 1,062 million) for each product as well as royalties on any commercialized
products.

'Since the introduction of our DuoBody platform in 2010, we have believed in
its potential to become the preferred technology for next generation bispecific
antibody therapeutics. Today's announcement is another indicator that the
pharmaceutical industry recognizes our leadership in the therapeutic antibody
field,' said Jan van de Winkel, Ph.D., Chief Executive Officer of Genmab. 'We
very much look forward to working with Janssen in creating trend-setting
bispecific antibody treatments.'

This agreement is not expected to have a material impact on Genmab's 2012
financial guidance.

About the DuoBody Platform
The DuoBody platform is an innovative platform for the discovery and
development of bispecific antibodies that may improve antibody therapy of
cancer, autoimmune, infectious and central nervous system disease. Bispecific
antibodies bind to two different epitopes either on the same, or on different
targets (also known as dual-targeting) which may improve the antibodies'
specificity and efficacy in inactivating the disease targets. DuoBody molecules
are unique in combining the benefits of bispecificity with the strengths of
conventional antibodies which allows DuoBody molecules to be administered and
dosed as other antibody therapeutics. Genmab's DuoBody platform generates
bispecific antibodies via a fast and broadly applicable process which is easily
performed at standard bench, as well as commercial, manufacturing scale.

About Genmab A/S
Genmab is a publicly traded, international biotechnology company specializing
in the creation and development of differentiated human antibody therapeutics
for the treatment of cancer. Founded in 1999, the company's first marketed
antibody, ofatumumab (Arzerra(r)), was approved to treat chronic lymphocytic
leukemia in patients who are refractory to fludarabine and alemtuzumab after
less than eight years in development. Genmab's validated and next generation
antibody technologies are expected to provide a steady stream of future product
candidates. Partnering of innovative product candidates and technologies is a
key focus of Genmab's strategy and the company has alliances with top tier
pharmaceutical and biotechnology companies. For more information visit
www.genmab.com.

Contact:
Rachel Curtis Gravesen, Senior Vice President, Investor Relations &
Communications
T: +45 33 44 77 20; M: +45 25 12 62 60; E: r.gravesen@genmab.com

This Company Announcement contains forward looking statements. The words
'believe', 'expect', 'anticipate', 'intend' and 'plan' and similar expressions
identify forward looking statements. Actual results or performance may differ
materially from any future results or performance expressed or implied by such
statements. The important factors that could cause our actual results or
performance to differ materially include, among others, risks associated with
pre-clinical and clinical development of products, uncertainties related to the
outcome and conduct of clinical trials including unforeseen safety issues,
uncertainties related to product manufacturing, the lack of market acceptance
of our products, our inability to manage growth, the competitive environment in
relation to our business area and markets, our inability to attract and retain
suitably qualified personnel, the unenforceability or lack of protection of our
patents and proprietary rights, our relationships with affiliated entities,
changes and developments in technology which may render our products obsolete,
and other factors. For a further discussion of these risks, please refer to the
risk management sections in Genmab's most recent financial reports, which are
available on www.genmab.com. Genmab does not undertake any obligation to update
or revise forward looking statements in this Company Announcement nor to
confirm such statements in relation to actual results, unless required by law.

Genmab(r); the Y-shaped Genmab logo(r); HuMax(r); HuMax-CD20(r); HuMax(r)-EGFr;
HuMax(r)-IL8; HuMax(r)-TAC; HuMax(r)-CD38; HuMax(r)-TF; HuMax(r)-TF-ADC; HuMax(r)-Her2;
HuMax(r)-cMet, HuMax(r)-CD74, DuoBody(tm) and UniBody(r) are all trademarks of Genmab
A/S. Arzerra(r) is a trademark of GlaxoSmithKline.

Company Announcement no. 17
CVR no. 2102 3884

Genmab A/S
Bredgade 34
1260 Copenhagen K
Denmark

Click on, or paste the following link into your web browser, to view the associated documents

https://newsclient.omxgroup.com/cds/DisclosureAttachmentServlet?messageAttachmentId=398325

News Source: NASDAQ OMX

12.07.2012 DGAP's Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
Media archive at www.dgap-medientreff.de and www.dgap.de

---

Language: English
Company: Genmab A/S

          Denmark

Phone:
Fax:
E-mail:
Internet:
ISIN: DK0010272202
WKN:

End of Announcement DGAP News-Service

---